

Table of Contents

Section I: General Information

Chapter 1	What are Combination Products?.....	1
Chapter 2	Regulatory Strategy.....	9

Section II: North America: US and Canada

Chapter 3	US FDA Structure, Office of Combination Products, and Combination Products Policy Council.....	17
Chapter 4	Jurisdiction and Regulatory Pathway	31
Chapter 5	Combination Product Development and Meetings	43
Chapter 6	Investigational Use and Human Factors	55
Chapter 7	Current Good Manufacturing Practice (CGMP)	67
Chapter 8	Marketing Applications, Premarket Review Pathways, and User Fees	77
Chapter 9	Combination Product Review Process and Labeling	93
Chapter 10	Postapproval Modifications.....	105
Chapter 11	Postmarket Safety Reporting	115
Chapter 12	Canadian Combination Products.....	127

Section III: Europe

Chapter 13	European Union Combination Products.....	143
	Acronyms	157
	Glossary.....	159
	Index.....	171

Figures

Figure 2-1.	Example Regulatory Strategy Document Template.....	14
Figure 3-1.	FDA Organization Leadership Chart.....	19
Figure 3-2.	CBER Leadership Chart	21

Figure 3-3. CDER Leadership Chart.....	23
Figure 3-4. CDRH Leadership Chart.....	26
Figure 4-1. Pre-RFD Process Flow	38
Figure 6-1. Interactions of Human Factors and Usability.....	61
Figure 7-1. Influence of Design Controls on the Design Process	75
Figure 8-1. CTD Triangle	80
Figure 8-2. Inter-Center Consult Request Process Map	86
Figure 13-1. EMA Organization Chart	146

Tables

Table 1-1. Nine Types of Combination Products.....	5
Table 2-1. Sample Questions to Inform the Regulatory Strategy	11
Table 2-2. Regulatory Submission Strategy Document Elements	13
Table 2-3. Regulatory Intelligence Resources.....	15
Table 3-1. Combination Products Policy Council Membership.....	28
Table 4-1. RFD and Pre-RFD Comparison	36
Table 5-1. Examples of Application-Based Mechanisms for Device-Led Combination Products	50
Table 5-2. Examples of Application-Based Mechanisms for Drug or Biological Product-Led Combination Products	51
Table 5-3. Submission Process for CPAM Requests.....	52
Table 7-1. Examples of Design Control Components	74
Table 8-1. Premarket Regulatory Pathways.....	78
Table 8-2. Code of Federal Regulation Link to eCTD.....	81
Table 10-1. Type of NDA/BLA Submission for a Change in a Device Constituent Part of a Combination Product Approved Under an NDA/BLA	109
Table 10-2. Type of PMA Submission for a Change in a Biological Product/Drug Constituent Part of a Combination Product Approved Under a PMA.....	110
Table 10-3. Postapproval Modifications by Constituent Part.....	111
Table 11-1. Safety Reporting Requirements—Single Application.....	118
Table 11-2. Postmarketing Safety Reports—FDA Locations	120
Table 11-3. Timelines for Various Combination Product PMSR Requirements	121
Table 13-1. EU Countries and Their Dates of Entry	144

Acknowledgements

On behalf of the Editorial Advisory Committee and author, Jocelyn Jennings, the Regulatory Affairs Professionals Society (RAPS) would like to express appreciation to the following subject matter experts who volunteered their time to review and provide valuable feedback on this first edition of *International Combination Products*.

Gert Bos, MSc, PhD, FRAPS
Executive Director and Partner
Qserve Consultancy BV
Netherlands

Beat U. Steffen, MSc, MBA
Founder and CEO
Confinis, AG
Switzerland

Viky Verna, MS BME, MS Pharm, RAC
Co-Founder and President (US office)
Confinis Corporation
US